Description
Introduction Of The Trastuzumab Emtansine (Ujvira):
Trastuzumab Emtansine (Ujvira), sometimes referred to as trastuzumab emtansine, is a drug used to treat breast cancer that is HER2-positive. Trastuzumab, a monoclonal antibody that specifically targets HER2-positive cells, is combined with DM1, a chemotherapeutic agent that prevents cell division.
Mode Of Action For Trastuzumab Emtansine (Ujvira):
Trastuzumab emtansine’s includes attaching to the HER2 protein on cancer cells’ surfaces, inhibiting its signalling pathways, and inducing the immune system to destroy the cancer cells. The chemotherapeutic drug DM1 is released from T-DM1 once it has entered the cell, killing the cancer cell.
Use Of Trastuzumab Emtansine (Ujvira):
Trastuzumab Emtansine (Ujvira) is used to treat HER2-positive breast cancer that has progressed to other parts of the body or that has returned after treatment. This is how ujvira infusion is used. When other therapies have failed or are no longer working, they are frequently utilised instead. Additionally, chemotherapy, radiation therapy, or hormonal therapy may all be used in conjunction with trastuzumab emtansine to treat certain types of cancer.
Benifits Of Trastuzumab Emtansine (Ujvira):
Patients with HER2-positive breast cancer benefit from better progression-free survival, overall survival, and quality of life because to trastuzumab emtansine. Like other chemotherapy medications, it is also generally well tolerated and has a decreased risk of side effects.
Reviews
There are no reviews yet.